| scholarly article | Q13442814 |
| P2093 | author name string | María Rodríguez-Muñoz | |
| Pilar Sánchez-Blázquez | |||
| Luis F Callado | |||
| J Javier Meana | |||
| Javier Garzón-Niño | |||
| P2860 | cites work | The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. | Q51750311 |
| No association of CNR1 gene variations with susceptibility to schizophrenia. | Q51977279 | ||
| [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. | Q52975728 | ||
| Elevated endogenous cannabinoids in schizophrenia | Q73029596 | ||
| Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticity | Q24642505 | ||
| Endocannabinoid signalling in the blood of patients with schizophrenia | Q24800061 | ||
| Cannabinoid receptor type-1: breaking the dogmas | Q26745261 | ||
| Involvement of CB1 cannabinoid receptors in emotional behaviour. | Q51055974 | ||
| Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date | Q27004490 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Cannabinoids and psychosis | Q28241328 | ||
| Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter | Q28245000 | ||
| A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action | Q28305159 | ||
| Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 | ||
| Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats | Q30437947 | ||
| Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients | Q30468799 | ||
| Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. | Q30497212 | ||
| Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens | Q30499463 | ||
| Imaging glutamate in schizophrenia: review of findings and implications for drug discovery | Q30685335 | ||
| The endocannabinoid system and psychiatric disorders | Q33547752 | ||
| Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia | Q33932087 | ||
| Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine | Q33941785 | ||
| Role of serotonin in central dopamine dysfunction. | Q34022787 | ||
| Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression | Q34065490 | ||
| The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system | Q34204641 | ||
| Regulation of NMDA Receptors by Dopamine D4Signaling in Prefrontal Cortex | Q34273323 | ||
| Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study | Q34394290 | ||
| Targeting of NMDA receptors in the treatment of major depression | Q34397015 | ||
| Decreased depression in marijuana users. | Q34427422 | ||
| From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment | Q34632695 | ||
| The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. | Q34659000 | ||
| Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment | Q34798544 | ||
| Region-specific dysregulation of glycogen synthase kinase-3β and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia | Q34873914 | ||
| Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. | Q34899462 | ||
| Src kinases: a hub for NMDA receptor regulation | Q35701114 | ||
| Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin | Q35722397 | ||
| Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report | Q36174333 | ||
| Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? | Q36251629 | ||
| NMDA receptors and schizophrenia. | Q36650010 | ||
| Alternatively spliced isoforms of the NMDARI receptor subunit | Q36682905 | ||
| Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions | Q36756365 | ||
| Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. | Q46535519 | ||
| N-methyl-D-aspartate receptor subtype mediated bidirectional control of p38 mitogen-activated protein kinase | Q46557740 | ||
| Dopamine D(1) and D(3) receptors oppositely regulate NMDA- and cocaine-induced MAPK signaling via NMDA receptor phosphorylation | Q46980708 | ||
| Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. | Q47781181 | ||
| A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain | Q48150235 | ||
| Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment. | Q48227373 | ||
| Monoamine dysfunction and the pathophysiology and treatment of depression | Q48349629 | ||
| Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression | Q48475678 | ||
| Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia | Q48532654 | ||
| Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. | Q48608235 | ||
| Differential expression of HINT1 in schizophrenia brain tissue | Q48874499 | ||
| G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors | Q48920822 | ||
| Cannabis use and brain structural alterations of the cingulate cortex in early psychosis | Q48987756 | ||
| Ketamine inhibits serotonin synthesis and metabolism in vivo | Q49014114 | ||
| Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system | Q49047040 | ||
| Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. | Q49157217 | ||
| Glutamate and dopamine in schizophrenia: an update for the 21st century | Q36992322 | ||
| Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials | Q37005419 | ||
| Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression | Q37128042 | ||
| Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress | Q37276946 | ||
| Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys | Q37309756 | ||
| Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls | Q37320669 | ||
| Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex. | Q37322477 | ||
| HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity | Q37364657 | ||
| Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons | Q37444391 | ||
| The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants | Q37592487 | ||
| Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces | Q37668134 | ||
| Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants | Q37812675 | ||
| The role of serotonin receptors in the action of atypical antipsychotic drugs | Q37855189 | ||
| Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. | Q38037679 | ||
| Ionotropic glutamate receptors: regulation by G-protein-coupled receptors. | Q38076636 | ||
| The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain. | Q38090227 | ||
| Therapeutic potential of cannabinoids in schizophrenia | Q38194178 | ||
| The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders | Q38262682 | ||
| Ketamine and other potential glutamate antidepressants | Q38281778 | ||
| Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study | Q38362304 | ||
| Role of calcium, glutamate and NMDA in major depression and therapeutic application | Q38369618 | ||
| Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial | Q38391268 | ||
| A quantitative review of the postmortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits? | Q38628411 | ||
| Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting | Q39386042 | ||
| The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. | Q39904357 | ||
| Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors | Q40027235 | ||
| Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. | Q40662659 | ||
| Do patients use marijuana as an antidepressant? | Q41478668 | ||
| Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction | Q42317501 | ||
| Activation-dependent plasticity of polarized GPCR distribution on the neuronal surface | Q42437175 | ||
| Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. | Q42872711 | ||
| The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control | Q43195386 | ||
| Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment | Q43299005 | ||
| Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. | Q43509575 | ||
| Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. | Q43581230 | ||
| Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms | Q44055486 | ||
| Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. | Q44334367 | ||
| Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord | Q44351566 | ||
| Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 | ||
| CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms | Q46109635 | ||
| Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. | Q46181398 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P921 | main subject | schizophrenia | Q41112 |
| endocannabinoid system | Q368952 | ||
| P304 | page(s) | 1291 | |
| P577 | publication date | 2017-12-18 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | Schizophrenia and depression, two poles of endocannabinoid system deregulation | |
| P478 | volume | 7 |
| Q64910138 | Altered Swimming Behaviors in Zebrafish Larvae Lacking Cannabinoid Receptor 2. |
| Q58732614 | Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor |
| Q94569525 | Endocannabinoid System Components as Potential Biomarkers in Psychiatry |
Search more.